In preclinical models, EGFR-targeted tyrosine kinase inhibitors quickly suppress PI3K-AKT, MAPK/ERK signaling in tumor cells, preventing tumor cell lines from proliferating in Swiss albino mice [70]. Here, MAPK1 is linked to neoplasm.